SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-132995
Filing Date
2020-05-05
Accepted
2020-05-05 07:09:40
Documents
14
Period of Report
2020-05-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d925223d8k.htm   iXBRL 8-K 32891
2 EX-99.1 d925223dex991.htm EX-99.1 93929
6 GRAPHIC g925223g0505032719024.jpg GRAPHIC 3606
  Complete submission text file 0001193125-20-132995.txt   276623

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20200501.xsd EX-101.SCH 3074
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20200501_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20200501_pre.xml EX-101.PRE 11410
11 EXTRACTED XBRL INSTANCE DOCUMENT d925223d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 20846816
SIC: 2834 Pharmaceutical Preparations